Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
COL6A1 expression as a potential prognostic biomarker for risk stratification of T1 high grade bladder cancer: Unveiling the aggressive nature of a distinct non-muscle invasive subtype.
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
- Additional Information
- Source:
Publisher: Korean Urological Association Country of Publication: Korea (South) NLM ID: 101674989 Publication Model: Print Cited Medium: Internet ISSN: 2466-054X (Electronic) Linking ISSN: 24660493 NLM ISO Abbreviation: Investig Clin Urol Subsets: MEDLINE
- Publication Information:
Original Publication: Seoul : Korean Urological Association, [2016]-
- Subject Terms:
- Abstract:
Purpose: T1 high grade (T1HG) bladder cancer (BC) is a type of non-muscle invasive BC (NMIBC) that is recognized as an aggressive subtype with a heightened propensity for progression. Current risk stratification methods for NMIBC rely on clinicopathological indicators; however, these approaches do not adequately capture the aggressive nature of T1HG BC. Thus, new, more accurate biomarkers for T1HG risk stratification are needed. Here, we enrolled three different patient cohorts and investigated expression of collagen type VI alpha 1 ( COL6A1 ), a key component of the extracellular matrix, at different stages and grades of BC, with a specific focus on T1HG BC.
Materials and Methods: Samples from 298 BC patients were subjected to RNA sequencing and real-time polymerase chain reaction.
Results: We found that T1HG BC and muscle invasive BC (MIBC) exhibited comparable expression of COL6A1 , which was significantly higher than that by other NMIBC subtypes. In particular, T1HG patients who later progressed to MIBC had considerably higher expression of COL6A1 than Ta, T1 low grade patients, and patients that did not progress, highlighting the aggressive nature and higher risk of progression associated with T1HG BC. Moreover, Cox and Kaplan-Meier survival analyses revealed a significant association between elevated expression of COL6A1 and poor progression-free survival of T1HG BC patients (multivariate Cox hazard ratio, 16.812; 95% confidence interval, 3.283-86.095; p=0.001 and p=0.0002 [log-rank test]).
Conclusions: These findings suggest that COL6A1 may be a promising biomarker for risk stratification of T1HG BC, offering valuable insight into disease prognosis and guidance of personalized treatment decisions.
Competing Interests: The authors have nothing to disclose.
(© The Korean Urological Association.)
- References:
Cancer Cell. 2016 Jul 11;30(1):27-42. (PMID: 27321955)
Cancer Immunol Immunother. 2018 Mar;67(3):403-412. (PMID: 29150702)
Eur Urol. 2008 May;53(5):992-1001. (PMID: 17950987)
BJU Int. 2012 Oct;110(8):1169-76. (PMID: 22448597)
Int J Oncol. 2021 Jul;59(1):. (PMID: 33982770)
Eur Urol. 2015 Nov;68(5):824-32; discussion 835-6. (PMID: 25770486)
J Oncol. 2022 Oct 25;2022:3016725. (PMID: 36330353)
Eur Urol. 2018 Nov;74(5):597-608. (PMID: 30017405)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Onco Targets Ther. 2019 May 07;12:3441-3457. (PMID: 31123405)
Int J Mol Sci. 2021 Feb 01;22(3):. (PMID: 33535616)
J Urol. 2017 Oct;198(4):817-823. (PMID: 28487100)
J Urol. 2016 Feb;195(2):493-8. (PMID: 26459038)
Cancer Biomark. 2019;24(2):183-193. (PMID: 30689556)
Clin Cancer Res. 2012 Nov 1;18(21):5865-5877. (PMID: 22932667)
J Urol. 2017 Feb;197(2S):S142-S145. (PMID: 28012770)
Nat Rev Urol. 2019 Jan;16(1):23-34. (PMID: 30323201)
J Urol. 2016 Oct;196(4):1021-9. (PMID: 27317986)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Eur Urol. 2022 Jan;81(1):75-94. (PMID: 34511303)
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7. (PMID: 16442208)
Comput Methods Programs Biomed. 2019 Aug;177:133-139. (PMID: 31319941)
Investig Clin Urol. 2016 Jun;57 Suppl 1:S44-51. (PMID: 27326407)
Int J Gen Med. 2022 Apr 05;15:3753-3765. (PMID: 35411173)
Mol Cancer. 2010 Jan 08;9:3. (PMID: 20059769)
J Clin Oncol. 2015 Feb 20;33(6):643-50. (PMID: 25559810)
Trends Mol Med. 2013 Jul;19(7):410-7. (PMID: 23639582)
- Grant Information:
2020R1I1A3062508 Korea NRF National Research Foundation of Korea; 2021R1I1A1A01050891 Korea NRF National Research Foundation of Korea; 2021RIS-001 Korea NRF National Research Foundation of Korea; 1345370811 Korea NRF National Research Foundation of Korea; 5199990614277 Korea NRF National Research Foundation of Korea; Korea KHIDI Korea Health Industry Development Institute
- Contributed Indexing:
Keywords: Collagen type VI; Non-muscle invasive bladder neoplasms; Progression-free survival; Risk assessment
- Publication Date:
Date Created: 20240110 Date Completed: 20240111 Latest Revision: 20240117
- Publication Date:
20240117
- Accession Number:
PMC10789541
- Accession Number:
10.4111/icu.20230227
- Accession Number:
38197756
No Comments.